• Home
  • NEW DAY MEDICINE
  • 1 (75) 2025
  • 45 -1 (75) 2025 - Mamedova G.G., Kahramanova S.M. - EFFICACY OF LOW-DOSE MONACOLIN K IN PATIENTS WITH MILD AND MODERATE DYSLIPIDEMIA

45 -1 (75) 2025 - Mamedova G.G., Kahramanova S.M. - EFFICACY OF LOW-DOSE MONACOLIN K IN PATIENTS WITH MILD AND MODERATE DYSLIPIDEMIA

EFFICACY OF LOW-DOSE MONACOLIN K IN PATIENTS WITH MILD AND MODERATE DYSLIPIDEMIA

Mamedova G.G. - Azerbaijan Medical University, Azerbaijan, Baku

Kahramanova S.M. - Azerbaijan Medical University, Azerbaijan, Baku

Azizov V.A. - Azerbaijan Medical University, Azerbaijan, Baku

Resume

Introduction: The article presents an analysis of a study investigating the role of red yeast rice, which exhibits statin-like effects due to the presence of monacolin K, in the primary prevention of cardiovascular diseases. Objective: To assess the lipid-lowering efficacy and safety of red yeast rice containing monacolin K, compared to diet therapy. Materials and Methods: A total of 25 patients with dyslipidemia and low to borderline cardiovascular risk were randomly divided into two groups: one group received a low dose of monacolin K alongside diet therapy, and the other group followed only diet therapy. The study lasted for 8 weeks, during which the efficacy and safety of monacolin K were evaluated. Results: The low dose of monacolin K combined with diet therapy led to a significant reduction in LDL-C levels by 2.57%, a decrease in total cholesterol by 1.01%, and an increase in HDL-C levels by 6.17%. No serious side effects were observed during the study. Conclusion: The results indicate the potential benefit of using monacolin K in the treatment of dyslipidemia in patients with low to moderate cardiovascular risk. Implications: Red yeast rice, which contains monacolin K, is well-tolerated and effectively lowers total cholesterol and LDL-C levels. This lipid-lowering nutraceutical can be used as an alternative method in primary prevention for individuals with low or borderline cardiovascular risk before initiating statin therapy, in cases of statin intolerance, or when patients do not adhere to statin treatment.

Keywords: Dyslipidemia, primary prevention, nutraceutical, red yeast rice, monacolin K.

First page

276

Last page

282

For citation:Mamedova G.G., Kahramanova S.M., Azizov V.A. - EFFICACY OF LOW-DOSE MONACOLIN K IN PATIENTS WITH MILD AND MODERATE DYSLIPIDEMIA//New Day in Medicine 1(75)2025 276-282 https://https://newdayworldmedicine.com/en/new_day_medicine/1-75-2025

List of References

  1. Bulletin of the World Health Organization, June 2018. (In Russ.) ВОЗ, Информационный бюллетень, 1 июня 2018 г. https://www.who.int/ru/news-room/ fact-sheets/detail/noncommunicable-diseases. Дата доступа: 01.09.2019.
  2. Sanidas E. The role of nutraceuticals in the treatment of primary dyslipidemia. //Hellenic Journal of Cardiology. 2018. doi:10.1016/j.hjc.2018.07.009
  3. Коллинз, Р.; Рейт, К.; Эмберсон, Дж.; Армитидж, Дж.; Бейджент, К.; Блэквелл, Л.; Блюменталь, Р.; Данеш, Дж.; Смит, Г. Д.; ДеМетс, Д.; и др. Интерпретация доказательств эффективности и безопасности терапии статинами. //Lancet 2016;388:2532-2561. [ Google Scholar ] [ CrossRef ] [ Green Version ]
  4. Гранди, SM; Стоун, NJ 2018 Американская ассоциация сердца/Американский колледж кардиологии. Многопрофильное руководство по контролю уровня холестерина в крови. //JAMA Cardiol. 2019;4:488-489. [ Google Scholar ] [ CrossRef ]
  5. Catapano AL; Graham I.; De Backer G.; Wiklund O.; Chapman MJ; Drexel H.; Hoes AW; Jennings CS; Landmesser U.; Pedersen T.R. et al. Рекомендации ESC/EAS по лечению дислипидемий 2016 г. //Атеросклероз 2016;253:281-344. [ Google Scholar ] [ CrossRef ] [ PubMed ] [ Green Version ]
  6. Globalization, diets and noncommunicable diseases. Geneva, World Health Organization, 2002 http://whqlibdoc.who.int/ publications/9241590416.pdf. (22 June 2021)
  7. De Backer GG. Food supplements with red yeast rice: more regulations are needed. //Eur J Prev Cardiol 2017;24:1429-1430
  8. 2018AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. //JACC. 2019;73(24). doi:10.1016/j.jacc.2018.11.003.
  9. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: supplementary data. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). //Eur Heart J. 2019;00:1-78. doi:10.1093/ eurheartj/ehz455.
  10. Adouridis A, Filippatos T, Tsimihodimos V, et al. Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism. //Expert Rev Cardiovasc Ther. 2011;9:355-66. doi:10.1586/erc.11.4
  11. Barrios V, Escobar C, Cicero AF, et al. A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence. //Atherosclerosis. 2017;24(Suppl.):1-15.
  12. Cicero АFG, Benvenuti C, ARMoweb study Group. Efficacy of a red yeast rice based nutraceutical in large subgroups of hypercholesterolemic subjects in every day clinical practice. //Mediterr J Nutr Metab. 2010;3:239-46.
  13. Sola R, Valls RM, Puzo J, et al. Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial. //PLoS One. 2014;9(8):e101978. doi:10.1371/journal.pone.0101978.
  14. Naci H, Brugts JJ, Fleurence R, et al. Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials. //Eur J Prev Cardiol. 2013;20:658-70.
  15. Weng TC, Yang YH, Lin SJ, et al. A systematic review and meta-analysis on the therapeutic equivalence of statins. //J Clin Pharm Therapeut. 2010;35:139-51.
  16. Catapano, A.L.; Graham, I.; De Backer, G.; Wiklund, O.; Chapman, M.J.; Drexel, H.; Hoes, A.W.; Jennings, C.S.; Landmesser, U.; Pedersen, T.R.; et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. //Atherosclerosis 2016;253:281-344. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Gerards, MC; Terlou, RJ; Yu, H.; Koks, CHW; Gerdes, VEA. Традиционное китайское гиполипидемическое средство — красный дрожжевой рис — приводит к значительному снижению уровня ЛПНП, но безопасность не определена — систематический обзор и метаанализ. //Atherosclerosis 2015;240:415-423. [ Google Scholar ] [ CrossRef ] [ Green Version ]
  18. Хайнц Т.; Шухардт Дж. П.; Мёллер К.; Хаджи П.; Хан А. Низкая суточная доза 3 мг монаколина К из RYR снижает концентрацию ЛПНП-Х в рандомизированном плацебо-контролируемом исследовании. //Nutr. Res. 2016;36:1162-1170.
  19. Беккер, DJ Красный дрожжевой рис при дислипидемии у пациентов с непереносимостью статинов. //Ann. Intern. Med. 2009;150:830. [Google Scholar ] [ CrossRef ]
  20. Halbert, SC; French, B.; Gordon, RY; Farrar, JT; Schmitz, K.; Morris, PB; Thompson, PD; Rader, DJ; Becker, DJ Переносимость красного дрожжевого риса (2400 мг дважды в день) по сравнению с правастатином (20 мг дважды в день) у пациентов с предыдущей непереносимостью статинов. //Am. J. Cardiol. 2010;105:198-204. [ Google Scholar ] [ CrossRef ]

    file

    download